Amanda Beasley
Adult Health · Lexington, NCNPI 1619125861
Payments from drug & device makers
Across 119 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$565
- Novo Nordisk$350
- Lilly USA, LLC$304
- Otsuka America Pharmaceutical, Inc.$188
- AstraZeneca$144
- Boehringer Ingelheim$77
- plus $385 from 11 others
What the payments were for
- Food & beverage$1,98699%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 41 | $565 |
| Novo Nordisk | 22 | $350 |
| Lilly USA, LLC | 10 | $304 |
| Otsuka America Pharmaceutical, Inc. | 9 | $188 |
| AstraZeneca | 10 | $144 |
| Boehringer Ingelheim | 4 | $77 |
| Astellas Pharma US Inc | 4 | $60 |
| Amgen | 4 | $53 |
| Sanofi-aventis U.S. LLC | 2 | $52 |
| Exact Sciences | 3 | $45 |
| GSK | 2 | $35 |
| Daiichi Sankyo Inc. | 2 | $34 |
| Bayer | 2 | $31 |
| Abbott | 1 | $25 |
| Pfizer | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPBOUND$119
How this compares
$2,013 in reported general payments places this provider in the 75th percentile of 614 adult health providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 94 | $124,155 |
| JardianceEmpagliflozin | 60 | $83,949 |
| MounjaroTirzepatide | 60 | $78,654 |
| RexultiBrexpiprazole | 39 | $59,758 |
| FarxigaDapagliflozin Propanediol | 47 | $53,480 |
| TrulicityDulaglutide | 36 | $52,860 |
| JanuviaSitagliptin Phosphate | 41 | $50,178 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $40,556 |
| SymbicortBudesonide/Formoterol Fumarate | 128 | $35,893 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $30,030 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $26,676 |
| LinzessLinaclotide | 24 | $22,082 |
| MyrbetriqMirabegron | 19 | $21,733 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $21,005 |
| Spiriva HandihalerTiotropium Bromide | 23 | $17,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $304 | $131,51496 claims |
| Novo NordiskOzempic | $350 | $124,15594 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $144 | $104,803199 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $77 | $99,10389 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $188 | $59,75839 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $35 | $47,68182 claims |
| AbbVieLinzess, Savella | $565 | $32,11835 claims |
| Astellas Pharma US IncMyrbetriq | $60 | $21,73319 claims |
| PfizerEliquis | $19 | $15,59713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 614 adult health providers in North Carolina.
Other adult health in Lexington
- Robert DodgeRaleigh$311K
- Kimberly CampDurham$147K
- Henry VanpalaRaleigh$110K
- Jolene SpencerWashington$83K
- Felicia RichardsonGreenville$64K
- Anna BooneReidsville$51K
- Chaely MedleyChapel Hill$47K
- Ann ShumDurham$35K
- Amy HopkinsGreenville$31K
- Stephanie YatesDurham$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.